279 related articles for article (PubMed ID: 20569446)
1. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.
Yhim HY; Kang HJ; Choi YH; Kim SJ; Kim WS; Chae YS; Kim JS; Choi CW; Oh SY; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Lee JJ; Sung HJ; Kim HJ; Lee DH; Suh C; Kwak JY
BMC Cancer; 2010 Jun; 10():321. PubMed ID: 20569446
[TBL] [Abstract][Full Text] [Related]
2. [Prognosis analysis of primary breast diffuse large B cell lymphoma].
Zhu YH; Meng WJ; He LH; Jia YS; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):235-240. PubMed ID: 30917462
[No Abstract] [Full Text] [Related]
3. Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors.
Validire P; Capovilla M; Asselain B; Kirova Y; Goudefroye R; Plancher C; Fourquet A; Zanni M; Gaulard P; Vincent-Salomon A; Decaudin D
Am J Hematol; 2009 Mar; 84(3):133-9. PubMed ID: 19199367
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
5. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.
Ryan G; Martinelli G; Kuper-Hommel M; Tsang R; Pruneri G; Yuen K; Roos D; Lennard A; Devizzi L; Crabb S; Hossfeld D; Pratt G; Dell'Olio M; Choo SP; Bociek RG; Radford J; Lade S; Gianni AM; Zucca E; Cavalli F; Seymour JF;
Ann Oncol; 2008 Feb; 19(2):233-41. PubMed ID: 17932394
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients.
Luo H; Yi P; Wang W; Li K; Meng L; Li J; Zeng W; Tang M
Med Sci Monit; 2019 Nov; 25():8671-8682. PubMed ID: 31734687
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study.
Lee SJ; Suh CW; Lee SI; Kim WS; Lee WS; Kim HJ; Choi CW; Kim JS; Shin HJ;
Korean J Intern Med; 2014 May; 29(3):352-60. PubMed ID: 24851070
[TBL] [Abstract][Full Text] [Related]
9. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.
Seker M; Bilici A; Ustaalioglu BO; Yilmaz B; Ozturk B; Ünal A; Dane F; Ozdemir NY; Elkiran ET; Kalender ME; Gumus M; Benekli M
Arch Gynecol Obstet; 2011 Aug; 284(2):405-9. PubMed ID: 20872226
[TBL] [Abstract][Full Text] [Related]
11. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
12. Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Multicenter Study of 272 Cases from the China Lymphoma Patient Registry.
Yang H; Wu M; Shen Y; Lei T; Mi L; Leng X; Ping L; Xie Y; Song Y; Cen X; Zhu J
Int J Med Sci; 2019; 16(7):1023-1031. PubMed ID: 31341416
[No Abstract] [Full Text] [Related]
13. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
14. Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas.
Lal A; Bhurgri Y; Vaziri I; Rizvi NB; Sadaf A; Sartajuddin S; Islam M; Kumar P; Adil S; Kakepoto GN; Masood N; Khurshed M; Alidina A
Asian Pac J Cancer Prev; 2008; 9(3):453-8. PubMed ID: 19004134
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
16. The impact of activated p-AKT expression on clinical outcomes in diffuse large B-cell lymphoma: a clinicopathological study of 262 cases.
Hong JY; Hong ME; Choi MK; Kim YS; Chang W; Maeng CH; Park S; Lee SJ; Do IG; Jo JS; Jung SH; Kim SJ; Ko YH; Kim WS
Ann Oncol; 2014 Jan; 25(1):182-8. PubMed ID: 24356628
[TBL] [Abstract][Full Text] [Related]
17. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
[TBL] [Abstract][Full Text] [Related]
18. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
20. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Winer ES; Olszewski AJ
Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
